About Cambrian Biopharma:
Cambrian Biopharma, a multi-asset longevity biotech, is building the medicines that will redefine healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health.
By partnering with leading academic institutions and biotech entrepreneurs all over the world, we are advancing a diversified pipeline of novel therapeutics, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve overall quality of life as we age.
Cambrian is a Distributed Development Company (or DisCo) which combines the advantages of a venture capital firm and a big pharmaceutical company, with the nimbleness of a biotech startup.
Cambrian’s sourcing and development engine allows us to identify promising science, deploy capital and teams of drug development experts, and provide stewardship to advance new medicines. By leveraging established expertise and repeatable functional models, we achieve vast efficiencies in execution speed and resource utilization.
To date, we have 14 novel therapeutics in development, and having closed a Series C financing round in October 2021 which raised $100 million, we plan to expand the number of programs. Further, we expect to initiate clinical trials for three programs in the next 18 months.
About the Cambrian Biomarkers Program:
The candidate will play a key role in a human clinical data-analytics program that will be deployed across Cambrian’s 15+ therapeutics under development. This innovative program will address regulatory challenges facing multi-disease preventative medicines by validating the causal linkages between age-related changes and age-related disease. Multiple academic groups and organizations have developed “aging clocks” that use individual biomarkers (e.g., DNA methylation patterns) to predict an individual’s likelihood of developing age-related disease. This program will apply advanced analytics to coalesce these distinct technologies into a single composite biomarker that can predict age-related multimorbidity risk: the likelihood of an individual developing any one of multiple age-related diseases. Thorough validation of such a biomarker could unlock a pathway to accelerated approval for healthspan therapeutics, making a larger number of these promising medicines available to patients faster.
The Vice President, Preemptive Medicine will design clinical strategy for Cambrian’s pipeline assets and manage a team to develop novel analytic and biomarker capabilities in support of that strategy. This person will be supported by a team of highly engaged colleagues with significant entrepreneurial and scientific experience including operations, R&D, and data science experts. The successful candidate will bring vision, strategy and leadership to develop and execute on biomarker strategies to enable drug development candidates to move through clinical development. Keys for success will include devising scientifically sound biomarker strategies, effective implementation of assays into clinical trials, and communicating data and program impacts to key stakeholders and project teams.
Cambrian Biopharma is proud to be an Equal Employment Opportunity and affirmative action employer. We celebrate diversity and do not discriminate based on race, color, religion, age, sex, national origin, disability status, genetics, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by federal, state, or local laws.
This policy applies to all terms and conditions of employment, including recruiting, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation, and training